ViroVet NV, a Belgian pionier in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that it has been presented with the best start-up of the year award for the second time. In 2015, the Biopharmaceutical company was already awarded for its concept and ideas, this time the jury granted the company for its progress and its ability to raise capital.
ViroVet NV uses a unique patented technology platform developed by the KU Leuven Rega Institute for Medical Research. This technology platform has the potential to produce vaccines faster and more cost-effective. These vaccines are designed to maximize effectiveness and minimize safety risks. Moreover, they are thermostable, so that the usual cold chain for distribution and storage is no longer necessary. ViroVet will use this technology for both endemic and epidemic viral diseases of livestock.